In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce new partnerships, report positive clinical trial results, and much more on the road to LSI Europe ‘25 in London (September 7-11).
Launched Kardia 12L, the company’s AI-powered, handheld 12-lead ECG system, in India following its successful U.S. debut. The CDSCO-approved device detects 35 cardiac determinations using a compact, reduced-lead design that enables faster, more accessible diagnosis in clinical settings.
Appointed George Adaniya to its Board of Directors, bringing decades of leadership across medical devices, pharma, aerospace, and industrial controls. His cross-sector experience and record of startup-to-exit success will support Amsel Medical’s growth and innovation strategy.
Reported positive data from the EMBO-02 study evaluating NeoCast™, a next-generation liquid embolic agent, for chronic subdural hematoma. Results showed rapid hematoma resorption, no injection pain, and 100% target vessel occlusion without NeoCast-related adverse events.
Closed an $11M oversubscribed Series A round to expand manufacturing and commercial rollout of Amma™, its FDA-cleared portable scalp cooling system. Funding will also support next-generation product development and growing access to hair-preserving therapy for chemotherapy patients.
Appointed Dave Demski to its Board of Directors and David Simon to its Scientific Advisory Team, strengthening leadership in robotic spine and cranial surgery. The additions bring decades of experience in surgical robotics, enabling technologies, and commercial strategy.
Announced updated national payor coverage with Aetna, designating the Nalu Neurostimulation System as medically necessary for chronic pain of peripheral nerve origin. The policy change expands access to Nalu’s minimally invasive PNS therapy for more than 22 million Aetna members across the U.S.
Announced a strategic alliance with Celestica to expand HoverTap™, NZTech’s next-generation human-machine interface platform, into rugged, high-demand environments like defense, industrial, and healthcare. The collaboration aims to position HoverTap as a new standard for interactive displays where conventional touchscreens fall short.
Received a €450K investment and closed an oversubscribed €1.2M Seed round led by ENEA Tech e Biomedical. The funds will support completion of the first-in-human clinical trial for the GROSSOⓇ Reshaper and further company developments.
Announced the closing of a $40M convertible notes financing by new investor Fidelity Management & Research Company. Proceeds will support the continued commercialization of its advanced shoulder implant systems and fund new product development.
Received a second U.S. patent for its Gen2 system, covering a novel dual-stimulation approach combining tACS and TMS to enhance memory. The Gen2 device is currently being tested in a multicenter Phase 2 study for early-stage Alzheimer’s disease.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy